programmed cell death 1 ligand 1, CAS No.rp174805, programmed cell death 1 (CD279)

Features and benefits
    Item Number
    rp174805
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp174805-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp174805-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90
    View related series
    programmed cell death 1 (CD279)

    Basic Description

    Product Nameprogrammed cell death 1 ligand 1, CAS No.rp174805
    SynonymsB7 homolog 1;B7-H1;PD-L1;PDL1;programmed death ligand 1
    GradeMoligand™
    Specifications & PurityMoligand™
    Mechanism of actionprogrammed cell death 1 (CD279)

    Associated Targets(Human)

    PDCD1 Tclin Programmed cell death protein 1 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp174805

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate NamesB7 homolog 1;B7-H1;PD-L1;PDL1;programmed death ligand 1
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Janakiram M, Abadi YM, Sparano JA, Zang X.  (2012)  T cell coinhibition and immunotherapy in human breast cancer..  Discov Med,  14  (77): (229-36).  [PMID:23114578]
    2. Greaves P, Gribben JG.  (2013)  The role of B7 family molecules in hematologic malignancy..  Blood,  121  (5): (734-44).  [PMID:23223433]
    3. Tang PA, Heng DY.  (2013)  Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer..  Curr Oncol Rep,  15  (2): (98-104).  [PMID:23263823]
    4. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA.  (2015)  Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy..  J Oncol Pharm Pract,  21  (6): (451-67).  [PMID:24917416]
    5. Johnson DB, Rioth MJ, Horn L.  (2014)  Immune checkpoint inhibitors in NSCLC..  Curr Treat Options Oncol,  15  (4): (658-69).  [PMID:25096781]
    6. Sasikumar PG, Ramachandra M.  (2017)  Small-molecule antagonists of the immune checkpoint pathways: concept to clinic..  Future Med Chem,  (12): (1305-1308).  [PMID:28771036]
    7. Miao X, Xu R, Fan B, Chen J, Li X, Mao W, Hua S, Li B.  (2018)  PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin..  Sci Rep,  (1): (1605).  [PMID:29371688]
    8. Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, Törner R, Skalniak L, Dömling A, Dubin G, Holak TA.  (2017)  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1..  J Med Chem,  60  (13): (5857-5867).  [PMID:28613862]

    Solution Calculators